Multinodular scleritis in a patient with rheumatoid arthritis

Ouederni, M.; Sahli, H.; Chéour, M.

doi:10.1007/s10067-021-05736-1

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anterior scleritis in RA can be necrotizing or non-necrotizing, which can again be diffuse or nodular. Nodular scleritis is associated with active RA and rheumatoid nodules and has good response to conventional-synthetic DMARDs and systemic steroids as found in a previous case report [1]. Necrotizing scleritis is a rare ocular manifestation of rheumatoid vasculitis with long-standing RA [2].…”

Section: Discussionmentioning

confidence: 77%

Bilateral scleromalacia in rheumatoid arthritis

Bhowmick

Roongta²,

Haldar³

et al. 2022

Clin Rheumatol

View full text Add to dashboard Cite

A 35-year-old lady presenting with deforming seropositive rheumatoid arthritis (RA) (Fig. 1a) of 8-year duration involving multiple small and large joints was initially on over-the-counter analgesics like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Five months back, she had high disease activity with a DAS28-CRP of 5.52 when she was put on methotrexate 15 mg per week and leflunomide 10 mg per day. Two months later she started complaining of acute onset pain, redness, and blurring of vision in both eyes. Her articular symptoms persisted with a DAS28-CRP of 5.2. Prior to the onset of the ocular symptoms, she had a good vision with no subjective complaints. Slit-lamp examination showed a violaceous hue of the bilateral bulbar sclera and dilated scleral vessels with areas of microvascular occlusion. Dilated retinal examination revealed cystoid macular edema (CME). She was diagnosed as having anterior necrotizing scleritis with CME and received high-dose systemic steroids with a rapid taper over 2 weeks along with topical steroid drops. There was no improvement in her vision though her joint pains and global symptoms improved partially. The dose of methotrexate and leflunomide was increased to 20 mg per week and 15 mg per day respectively in view of high disease activity. Two months back, she was admitted with visual acuity of 6/18 in the right eye and 6/36 in the left eye. Her DAS28-CRP was 4.92 at the time of admission. After ruling out tuberculosis, syphilis, and herpes infection, she received 5 mg/kg infliximab at 0, 2, and 6 weeks, which improved her vision to 6/9 and 6/12 in her right and left eye respectively. Methotrexate was continued, and leflunomide * Rashmi Roongta

show abstract

Section: Discussionmentioning

confidence: 77%

Bilateral scleromalacia in rheumatoid arthritis

Bhowmick

Roongta²,

Haldar³

et al. 2022

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…[83][84][85][86] In addition, untreated chronic inflammation may lead to renal amyloidosis, 87,88 rheumatoid nodules in the skin, [89][90][91] and interstitial lung disease (ILD). [92][93][94][95] Moreover, in the eye, episcleritis is common, [96][97][98] liver problems like autoimmune hepatitis can also trigger problems, [99][100][101] and peripheral neuropathy caused by wrist swelling and median nerve compression is a common problem in carpal tunnel syndrome. Rheumatic diseases of the spine can also contribute to myelopathy, atlantoaxial subluxation may occur due to erosion of the transverse ligament, and can progress to paralysis and even death.…”

Section: Risk Factors and Symptomsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

109

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

show abstract

Multinodular scleritis in a patient with rheumatoid arthritis

Cited by 2 publications

References 4 publications

Bilateral scleromalacia in rheumatoid arthritis

Bilateral scleromalacia in rheumatoid arthritis

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Contact Info

Product

Resources

About